Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond
Hui-li Wong, Michael Christie, Lucy Gately, Jeanne Tie, Belinda Lee, Christine Semira, Sheau Wen Lok, Rachel Wong, Peter Gibbs
FUTURE ONCOLOGY | FUTURE MEDICINE LTD | Published : 2018
While mismatch repair (MMR) deficiency has been studied extensively, the assessment of MMR status in colorectal and other cancers remains highly relevant, particularly in light of recent data demonstrating that MMR deficiency is a strong predictor for treatment benefit with immune checkpoint inhibitors across multiple tumor types. In colorectal cancer, there is a growing consensus in support of routine MMR testing for Lynch syndrome screening, to inform prognosis and adjuvant chemotherapy use in early stage disease, and to predict response to immunotherapy in advanced disease. Here, we provide a review of the Ventana MMR Immunohistochemistry Panel, which was recently approved by the US FDA f..View full abstract
M Christie, J Tie and P Gibbs have received research support from Ventana Medical Systems, Inc. for their institution. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.